NEWPORT, Ky., July 13 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, today announced the appointment of three new members to its executive management team. Joining the company are Natasha Giordano, Chief Commercial Officer; Rita O'Connor, Chief Financial & Information Officer; and Peter Wentworth, Senior Vice President, Human Resources.
Commenting on these appointments, CEO Michael J. Valentino said, "I am excited to welcome Natasha, Rita, and Peter to the Xanodyne management team. Each of them brings a diverse and proven track record of building and leading high growth organizations within the pharmaceutical industry. Their collective experience should contribute significantly to the anticipated rapid growth and commercial success of our company."
Ms. Giordano has more than 25 years of experience in the healthcare and pharmaceutical industry and most recently served as President Americas at Cegedim Dendrite, a global sales and marketing solutions and information company specializing in the pharmaceutical industry. Her depth of experience includes senior leadership positions in general management, marketing, compliance, and sales at major pharmaceutical companies including Pfizer and Parke-Davis.
Ms. O'Connor joins Xanodyne from NPS Pharmaceuticals where she served as Vice President, Finance. Previously, she was Chief Financial Officer and Treasurer at Adams Respiratory Therapeutics. With nearly 20 years of finance and accounting experience in the pharmaceutical industry, O'Connor is a certified public accountant and has held leadership positions at Schering-Plough and Deloitte & Touche. She also serves on the Board of Directors at the Essential Group Inc.
Mr. Wentworth has extensive experien
|SOURCE Xanodyne Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved